$MCRB
Seres Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016019550 Filed on May 16, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $2.710M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.210M $2.610M
YoY Change 176.25% 307.81%
% of Gross Profit
Research & Development $15.42M $5.561M
YoY Change 177.22% 439.9%
% of Gross Profit
Depreciation & Amortization $386.0K $92.00K
YoY Change 319.57%
% of Gross Profit
Operating Expenses $22.63M $8.167M
YoY Change 177.04% 388.46%
Operating Profit -$19.92M -$8.167M
YoY Change 143.86% 388.46%
Interest Expense $270.0K $210.0K
YoY Change 28.57% 950.0%
% of Operating Profit
Other Income/Expense, Net $212.0K $196.0K
YoY Change 8.16% -590.0%
Pretax Income -$19.70M -$7.970M
YoY Change 147.18% 371.6%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.70M -$7.971M
YoY Change 147.2% 371.94%
Net Earnings / Revenue -727.08%
Basic Earnings Per Share
Diluted Earnings Per Share -$502.7K -$210.7K
COMMON SHARES
Basic Shares Outstanding 39.19M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $303.3M $104.3M
YoY Change 190.8%
Cash & Equivalents $193.2M $45.05M
Short-Term Investments $110.1M $59.30M
Other Short-Term Assets $3.600M $800.0K
YoY Change 350.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $306.8M $105.1M
YoY Change 191.91%
LONG-TERM ASSETS
Property, Plant & Equipment $16.10M $1.300M
YoY Change 1138.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.500M $2.200M
YoY Change -31.82%
Total Long-Term Assets $17.70M $3.500M
YoY Change 405.71%
TOTAL ASSETS
Total Short-Term Assets $306.8M $105.1M
Total Long-Term Assets $17.70M $3.500M
Total Assets $324.5M $108.6M
YoY Change 198.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.800M $1.100M
YoY Change 427.27%
Accrued Expenses $1.200M $300.0K
YoY Change 300.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M
YoY Change
Total Short-Term Liabilities $24.82M $3.400M
YoY Change 630.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.000M
YoY Change -100.0%
Other Long-Term Liabilities $109.8M $1.400M
YoY Change 7742.86%
Total Long-Term Liabilities $109.8M $2.400M
YoY Change 4475.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.82M $3.400M
Total Long-Term Liabilities $109.8M $2.400M
Total Liabilities $134.6M $5.800M
YoY Change 2221.36%
SHAREHOLDERS EQUITY
Retained Earnings -$102.3M
YoY Change
Common Stock $292.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $189.8M $102.8M
YoY Change
Total Liabilities & Shareholders Equity $324.5M $108.6M
YoY Change 198.77%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$19.70M -$7.971M
YoY Change 147.2% 371.94%
Depreciation, Depletion And Amortization $386.0K $92.00K
YoY Change 319.57%
Cash From Operating Activities $101.4M -$8.300M
YoY Change -1321.69% 492.86%
INVESTING ACTIVITIES
Capital Expenditures $3.400M $214.0K
YoY Change 1488.79% -314.0%
Acquisitions
YoY Change
Other Investing Activities $21.10M -$59.30M
YoY Change -135.58%
Cash From Investing Activities $17.70M -$59.50M
YoY Change -129.75% 59400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K -1.300M
YoY Change -115.38% -360.0%
NET CHANGE
Cash From Operating Activities 101.4M -8.300M
Cash From Investing Activities 17.70M -59.50M
Cash From Financing Activities 200.0K -1.300M
Net Change In Cash 119.3M -69.10M
YoY Change -272.65% 6810.0%
FREE CASH FLOW
Cash From Operating Activities $101.4M -$8.300M
Capital Expenditures $3.400M $214.0K
Free Cash Flow $98.00M -$8.514M
YoY Change -1251.05% 554.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 mcrb Deferred Revenue Current Related Party
DeferredRevenueCurrentRelatedParty
12000000
CY2015Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2016Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
39000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291998000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
108000
CY2016Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24822000
CY2016Q1 mcrb Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
4527000
CY2016Q1 mcrb Deferred Revenue Noncurrent Related Party
DeferredRevenueNoncurrentRelatedParty
105290000
CY2016Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
30000
CY2016Q1 us-gaap Liabilities
Liabilities
134639000
CY2015Q4 us-gaap Liabilities
Liabilities
11506000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
39000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287937000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102316000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82612000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
189829000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
205394000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324468000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
216900000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15416000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5561000
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39218702
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
87000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
54000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
131149000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
386000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39082017
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39218702
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39082017
CY2016Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2710000
CY2016Q1 us-gaap Revenues
Revenues
2710000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7210000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2606000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
22626000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8167000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19916000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8167000
CY2016Q1 us-gaap Interest Income Other
InterestIncomeOther
268000
CY2015Q1 us-gaap Interest Income Other
InterestIncomeOther
49000
CY2016Q1 us-gaap Interest Expense Other
InterestExpenseOther
56000
CY2015Q1 us-gaap Interest Expense Other
InterestExpenseOther
66000
CY2015Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
213000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
212000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
196000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19704000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-7971000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39186130
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6912725
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
78000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
78000
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
31000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19626000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7940000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3904000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1327000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-213000
CY2016Q1 mcrb Noncash Interest Expense
NoncashInterestExpense
54000
CY2015Q1 mcrb Noncash Interest Expense
NoncashInterestExpense
30000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1040000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
710000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
117290000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1331000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-189000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-806000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-706000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
101415000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8340000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3400000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
45301000
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
59255000
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
66425000
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17723000
CY2016Q1 mcrb Proceeds From Exercise Of Stock Options And Common Stock Warrants
ProceedsFromExerciseOfStockOptionsAndCommonStockWarrants
157000
CY2015Q1 mcrb Proceeds From Exercise Of Stock Options And Common Stock Warrants
ProceedsFromExerciseOfStockOptionsAndCommonStockWarrants
89000
CY2015Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300000
CY2015Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1096000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
157000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-59469000
CY2015Q1 mcrb Payments For Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Cost
PaymentsForProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCost
-24000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1331000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3395000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
119295000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-69140000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114185000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45045000
CY2016Q1 us-gaap Interest Paid
InterestPaid
10000
CY2015Q1 us-gaap Interest Paid
InterestPaid
40000
CY2015Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
162000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p></div>
CY2016Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain amounts reported in the prior year financial statements have been reclassified for comparative purposes to conform with the presentation in the current year condensed consolidated financial statements.</p></div>
CY2016Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2010-10-31
CY2016Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
State of Delaware
CY2016Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2016Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2016Q1 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
109941000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
109000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
110050000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
131116000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
136945000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
93314000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
45250000
CY2015Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
91974000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.59
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3904000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1327000
CY2016Q1 mcrb Period Of Performance Identifiable Deliverables
PeriodOfPerformanceIdentifiableDeliverables
P10Y
CY2015Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0183
CY2015Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P8Y6M
CY2015Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.800
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38000000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5026246
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
992625
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
136685
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5882186
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-01-31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1892915
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5756568
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.01
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.52
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.15
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.46
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.66
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.34
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M5D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y18D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M1D
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17479000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8762000
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1397000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1011000
CY2016Q1 mcrb Accrued Development And Manufacturing Costs Current
AccruedDevelopmentAndManufacturingCostsCurrent
2093000
CY2015Q4 mcrb Accrued Development And Manufacturing Costs Current
AccruedDevelopmentAndManufacturingCostsCurrent
1436000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1187000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2756000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
498000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184000
CY2016Q1 mcrb Accrued Facility Current
AccruedFacilityCurrent
3128000
CY2015Q4 mcrb Accrued Facility Current
AccruedFacilityCurrent
1053000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
153000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94000
CY2016Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
0
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06

Files In Submission

Name View Source Status
0001564590-16-019550-index-headers.html Edgar Link pending
0001564590-16-019550-index.html Edgar Link pending
0001564590-16-019550.txt Edgar Link pending
0001564590-16-019550-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcrb-10q_20160331.htm Edgar Link pending
mcrb-20160331.xml Edgar Link completed
mcrb-20160331.xsd Edgar Link pending
mcrb-20160331_cal.xml Edgar Link unprocessable
mcrb-20160331_def.xml Edgar Link unprocessable
mcrb-20160331_lab.xml Edgar Link unprocessable
mcrb-20160331_pre.xml Edgar Link unprocessable
mcrb-ex101_534.htm Edgar Link pending
mcrb-ex103_260.htm Edgar Link pending
mcrb-ex311_6.htm Edgar Link pending
mcrb-ex312_9.htm Edgar Link pending
mcrb-ex321_8.htm Edgar Link pending
mcrb-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending